Nyxoah (NYXH) Net Income towards Common Stockholders (2021 - 2026)
Nyxoah (NYXH) posted quarterly Net Income towards Common Stockholders of $19.0 million for Q1 2026, down 19.19% year-over-year from $23.5 million in Q1 2025, and down 99.93% quarter-over-quarter from $27.4 billion in Q4 2025.
Nyxoah (NYXH) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Nyxoah's Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at $19.0 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 19.19% year-over-year to $19.0 million; the TTM figure through Mar 2026 stood at $27.4 billion (up 249.9% YoY), while the FY2025 annual figure was -$104.9 million, down 65.66% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at $19.0 million, down from $27.4 billion in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $27.4 billion in Q4 2025, with the low at -$18.3 billion in Q4 2024.
- The 5-year median for Net Income towards Common Stockholders is $14.0 million (2023), against an average of $1.4 billion.
- The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders surged 167934.78% in 2023, then tumbled 245.57% in 2025.
- Nyxoah's Net Income towards Common Stockholders stood at $13.6 billion in 2022, then slumped by 186.32% to -$11.7 billion in 2023, then tumbled by 56.36% to -$18.3 billion in 2024, then jumped by 249.36% to $27.4 billion in 2025, then plunged by 99.93% to $19.0 million in 2026.
- Business Quant data shows NYXH's Net Income towards Common Stockholders at $19.0 million in Q1 2026, $27.4 billion in Q4 2025, and -$27.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 823.20 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | 378.00 Mn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | - |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 383.43 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 139.00 Mn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 147.90 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 93.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | -77.90 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 126.00 Mn |
| 10 | Nyxoah | 90.94 Mn | 90.94 Mn | 5.33 Mn | -38.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -38.32 Mn |
| Mar 31, 2026 | 19.03 Mn |
| Dec 31, 2025 | 27.37 Bn |
| Sep 30, 2025 | -27.60 Mn |
| Jun 30, 2025 | 23.06 Mn |
| Mar 31, 2025 | 23.55 Mn |
| Dec 31, 2024 | -18.33 Bn |
| Sep 30, 2024 | 18.96 Mn |
| Jun 30, 2024 | 14.22 Mn |
| Mar 31, 2024 | 12.93 Mn |
| Dec 31, 2023 | -11.72 Bn |
| Sep 30, 2023 | -8.30 Mn |
| Jun 30, 2023 | 13.99 Mn |
| Mar 31, 2023 | 12.81 Bn |
| Dec 31, 2022 | 13.58 Bn |
| Sep 30, 2022 | -6.29 Mn |
| Jun 30, 2022 | 5.34 Mn |
| Mar 31, 2022 | -7.64 Mn |
| Dec 31, 2021 | 7.24 Bn |
| Sep 30, 2021 | 10.40 Mn |